In COVID-19 clinical update #84, Dr. Griffin discusses childrens’ antibody response to vaccination, phase 3 results of Novavax vaccine, heterologous vaccination, antithrombotic therapy, EUA for molnupiravir, phase 3 results of AZD7442, serum ferritin levels and outcomes, heparin therapy, and WHO strategy for global vaccination.

Hosts: Daniel Griffin and Vincent Racaniello   Subscribe (free): iTunes, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Antibody profiles after mRNA vaccination in children (bioRxiv)
• Novavax vaccine phase 3 results (medRxiv)
• Heterologous vaccine boosters (medRxiv)
• Antithrombotic therapy outcomes (JAMA)
• Molnupiravir EUA submitted (Merck)
• AZD7442 phase 3 results (AstraZeneca)
• Serum ferritin levels and disease outcome (JAMA)
• Heparin efficacy (JAMA)
• WHO strategy to vaccinate world (WHO)
• Letters read on TWiV 817
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]